TP53 and infection: Indeed, standard chemotherapy has been progressively replaced by targeted therapies, as they are safer and more manageable with lower incidence of toxicities, including cytopenias, infections, and secondary malignancies, and higher efficacy compared to chemotherapy, especially in those subjects with TP53 mutations, del(11q), and IGHV unmutated (31–34).